WO2002058718A2 - Methodes et compositions permettant de stimuler l'angiogenese - Google Patents
Methodes et compositions permettant de stimuler l'angiogenese Download PDFInfo
- Publication number
- WO2002058718A2 WO2002058718A2 PCT/US2002/001666 US0201666W WO02058718A2 WO 2002058718 A2 WO2002058718 A2 WO 2002058718A2 US 0201666 W US0201666 W US 0201666W WO 02058718 A2 WO02058718 A2 WO 02058718A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pdgf
- fgf
- vegf
- angiogenesis
- tissue
- Prior art date
Links
- 230000033115 angiogenesis Effects 0.000 title claims abstract description 55
- 230000001737 promoting effect Effects 0.000 title claims abstract description 21
- 108010081589 Becaplermin Proteins 0.000 title claims description 116
- 239000000203 mixture Substances 0.000 title claims description 10
- 239000002870 angiogenesis inducing agent Substances 0.000 claims abstract description 66
- 238000000034 method Methods 0.000 claims abstract description 58
- 230000006444 vascular growth Effects 0.000 claims abstract description 8
- 239000003094 microcapsule Substances 0.000 claims description 61
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 52
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims description 47
- 229920002684 Sepharose Polymers 0.000 claims description 43
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 37
- 229920000669 heparin Polymers 0.000 claims description 37
- 229960002897 heparin Drugs 0.000 claims description 37
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 36
- 229940072056 alginate Drugs 0.000 claims description 36
- 235000010443 alginic acid Nutrition 0.000 claims description 36
- 229920000615 alginic acid Polymers 0.000 claims description 36
- 239000013598 vector Substances 0.000 claims description 34
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 25
- 238000002347 injection Methods 0.000 claims description 25
- 239000007924 injection Substances 0.000 claims description 25
- 239000011324 bead Substances 0.000 claims description 24
- 239000000560 biocompatible material Substances 0.000 claims description 21
- 208000028867 ischemia Diseases 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 229920000642 polymer Polymers 0.000 claims description 15
- 210000004204 blood vessel Anatomy 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 239000002202 Polyethylene glycol Substances 0.000 claims description 9
- 229920001223 polyethylene glycol Polymers 0.000 claims description 9
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 claims description 8
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 claims description 8
- 230000001177 retroviral effect Effects 0.000 claims description 8
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 claims description 7
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 claims description 7
- 238000002513 implantation Methods 0.000 claims description 7
- -1 cationic lipid Chemical class 0.000 claims description 6
- 239000010410 layer Substances 0.000 claims description 6
- 108010059616 Activins Proteins 0.000 claims description 5
- 102000009088 Angiopoietin-1 Human genes 0.000 claims description 5
- 108010048154 Angiopoietin-1 Proteins 0.000 claims description 5
- 102000009075 Angiopoietin-2 Human genes 0.000 claims description 5
- 108010048036 Angiopoietin-2 Proteins 0.000 claims description 5
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims description 5
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims description 5
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 claims description 5
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 5
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 5
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims description 5
- 101800004490 Endothelin-1 Proteins 0.000 claims description 5
- 108090000394 Erythropoietin Proteins 0.000 claims description 5
- 102000003951 Erythropoietin Human genes 0.000 claims description 5
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 5
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims description 5
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 5
- 108090000378 Fibroblast growth factor 3 Proteins 0.000 claims description 5
- 102100028043 Fibroblast growth factor 3 Human genes 0.000 claims description 5
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 claims description 5
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 claims description 5
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 claims description 5
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 claims description 5
- 108090000382 Fibroblast growth factor 6 Proteins 0.000 claims description 5
- 102100028075 Fibroblast growth factor 6 Human genes 0.000 claims description 5
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 claims description 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 5
- 102100026818 Inhibin beta E chain Human genes 0.000 claims description 5
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 5
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 5
- 108050009450 Neuropilin Proteins 0.000 claims description 5
- 102000002111 Neuropilin Human genes 0.000 claims description 5
- 108010081689 Osteopontin Proteins 0.000 claims description 5
- 102000004264 Osteopontin Human genes 0.000 claims description 5
- 102100040681 Platelet-derived growth factor C Human genes 0.000 claims description 5
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 claims description 5
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 claims description 5
- 239000000488 activin Substances 0.000 claims description 5
- 229940105423 erythropoietin Drugs 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 108010017843 platelet-derived growth factor A Proteins 0.000 claims description 5
- 108010017992 platelet-derived growth factor C Proteins 0.000 claims description 5
- 102000005162 pleiotrophin Human genes 0.000 claims description 5
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 5
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 5
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 4
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 4
- 230000017531 blood circulation Effects 0.000 claims description 4
- 238000005516 engineering process Methods 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- XEPXGZZWVKNRGS-GQYPCLOQSA-N n-[(3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]octanamide Chemical compound CCCCCCCC(=O)NC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XEPXGZZWVKNRGS-GQYPCLOQSA-N 0.000 claims description 4
- 239000013603 viral vector Substances 0.000 claims description 4
- SCRCZNMJAVGGEI-UHFFFAOYSA-N 1,4-dioxane-2,5-dione;oxepan-2-one Chemical compound O=C1COC(=O)CO1.O=C1CCCCCO1 SCRCZNMJAVGGEI-UHFFFAOYSA-N 0.000 claims description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 3
- 229920000954 Polyglycolide Polymers 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 3
- 229950010732 poliglecaprone Drugs 0.000 claims description 3
- 239000004633 polyglycolic acid Substances 0.000 claims description 3
- 238000003259 recombinant expression Methods 0.000 claims description 3
- 239000002356 single layer Substances 0.000 claims description 3
- 102100033902 Endothelin-1 Human genes 0.000 claims 3
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims 3
- 230000006698 induction Effects 0.000 claims 3
- 101150019331 FGF2 gene Proteins 0.000 claims 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 229920000729 poly(L-lysine) polymer Polymers 0.000 claims 2
- 229920000936 Agarose Polymers 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- 101150088952 IGF1 gene Proteins 0.000 claims 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 claims 1
- 239000001506 calcium phosphate Substances 0.000 claims 1
- 239000005038 ethylene vinyl acetate Substances 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims 1
- 229920000747 poly(lactic acid) Polymers 0.000 claims 1
- 229920002492 poly(sulfone) Polymers 0.000 claims 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
- 229940078499 tricalcium phosphate Drugs 0.000 claims 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims 1
- 235000019731 tricalcium phosphate Nutrition 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 description 39
- 241000699670 Mus sp. Species 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 28
- 108010082117 matrigel Proteins 0.000 description 28
- 230000002491 angiogenic effect Effects 0.000 description 25
- 241000700159 Rattus Species 0.000 description 22
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 22
- 210000004088 microvessel Anatomy 0.000 description 22
- 239000008188 pellet Substances 0.000 description 20
- 239000002775 capsule Substances 0.000 description 17
- 238000001727 in vivo Methods 0.000 description 17
- 239000013613 expression plasmid Substances 0.000 description 16
- 239000003102 growth factor Substances 0.000 description 16
- 210000003098 myoblast Anatomy 0.000 description 15
- 230000003389 potentiating effect Effects 0.000 description 11
- 102000008076 Angiogenic Proteins Human genes 0.000 description 10
- 108010074415 Angiogenic Proteins Proteins 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 210000003489 abdominal muscle Anatomy 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 210000004087 cornea Anatomy 0.000 description 9
- 230000000302 ischemic effect Effects 0.000 description 9
- 238000011179 visual inspection Methods 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 239000012148 binding buffer Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 7
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 239000005090 green fluorescent protein Substances 0.000 description 7
- 230000004217 heart function Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 208000010125 myocardial infarction Diseases 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 206010061216 Infarction Diseases 0.000 description 6
- 230000003187 abdominal effect Effects 0.000 description 6
- 230000003302 anti-idiotype Effects 0.000 description 6
- 230000007574 infarction Effects 0.000 description 6
- 210000005166 vasculature Anatomy 0.000 description 6
- 230000002861 ventricular Effects 0.000 description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 210000004165 myocardium Anatomy 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 230000003248 secreting effect Effects 0.000 description 5
- 241000700605 Viruses Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000001110 calcium chloride Substances 0.000 description 4
- 229910001628 calcium chloride Inorganic materials 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000003278 mimic effect Effects 0.000 description 4
- 208000031225 myocardial ischemia Diseases 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 206010034576 Peripheral ischaemia Diseases 0.000 description 3
- 230000006427 angiogenic response Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- 102400000686 Endothelin-1 Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 2
- 208000021328 arterial occlusion Diseases 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 239000011885 synergistic combination Substances 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000000779 thoracic wall Anatomy 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010069729 Collateral circulation Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 239000004792 Prolene Substances 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 102000055277 human IL2 Human genes 0.000 description 1
- 102000058223 human VEGFA Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 201000002818 limb ischemia Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 230000026341 positive regulation of angiogenesis Effects 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Definitions
- tissue ischemias including myocardial ischemia, ischaemic bowel disease, and peripheral ischemia.
- the alleviation of tissue ischemia is critically dependent upon angiogenesis, the process by which new capillaries are generated from existing vasculature and tissue.
- the spontaneous growth of new blood vessels provide collateral circulation in and around an ischemic area, improves blood flow, and alleviates the symptoms caused by the ischemia.
- surgery or angioplasty may help to revascularize ischemic regions in some cases, the extent, complexity and location of the arterial lesions which cause the occlusion often prohibits such treatment.
- the present invention provides novel methods and compositions for promoting angiogenesis to treat a variety of tissue ischemias, including peripheral and myocardial ischemia.
- Selected angiogenic factors or synergistic combinations of factors, functional analogues of such factors or combinations of factors, or nucleic acids encoding such factors or combinations of factors are delivered to a localized area of tissue in an amount effective to induce angiogenesis within the area of tissue.
- the invention further includes improved methods and vehicles for delivering such factors or combinations of factors, functional analogues of such factors or combinations of factors, and nucleic acids encoding such factors or combinations of factors.
- the invention provides a method of promoting angiogenesis comprising delivering PDGF-BB to a localized area of tissue in an amount effective to induce angiogenesis within the area of tissue.
- the PDGF-BB can be delivered either alone or in combination with another angiogenesis-promoting factor, particularly bFGF and/or NEGF-A.
- the angiogenesis-promoting factor or combination of factors can be administered in the form of a protein composition or an expression plasmid encoding the protein(s).
- the angiogenesis-promoting factor or combination of factors can also be administered in the form of functional analogues of the factor or combination of factors.
- anti-idiotypic antibodies of PDGF-BB, NEGF-A and/or bFGF can be administered in accordance with the invention.
- suitable vectors include, but are not limited to, adenoviral vectors, retroviral vectors, adeno-associated viral vectors, R ⁇ A vectors, liposomes, cationic lipids, lentiviral vectors and transposons.
- the invention provides a method for promoting angiogenesis by delivering angiogenic factors, such as those described above, to a localized area of tissue using heparin sepharose-containing microcapsules in an amount effective to induce angiogenesis within the area of tissue.
- the angiogenic factors or expression plasmids encoding the factors are incorporated into the microcapsules as described in the working examples provided below for slow, sustained release into localized areas of tissue.
- the microcapsules are made up of uncoated heparin sepharose beads, heparin sepharose beads coated with a single layer of alginate polymer, heparin sepharose beads coated with poly-ethylene glycol (PEG) polymer or heparin sepharose beads coated with alternating layers of alginate and PEG.
- the microcapsules range in size from 1-200 microns.
- Suitable angiogenic factors for incorporating into the microcapsules include, for example, M-CSF, GM-CSF, NEGF-A, VEGF-B, VEGF-C, NEGF-D, VEGF-E, neuropilin, FGF-1 , FGF-2(bFGF), FGF-3, FGF-4, FGF-5, FGF-6, PDGF-BB, PDGF- AA, Angiopoietin 1, Angiopoietin 2, erythropoietin, BMP-2, BMP-4, BMP-7, TGF- beta, IGF-1, Osteopontin, Pleiotropin, Activin, Endothelin-1, and combinations thereof or an expression vectors encoding such angiogenic factors.
- the angiogenic factors can be purified from their native sources or produced by recombinant expression.
- the microcapsules are contacted with the localized area of tissue generally by injection or surgical implantation.
- injection can be performed using a catheter based trans-myocardial injection technology, such as the ⁇ OGA technology.
- the present invention provides a method for promoting angiogenesis by contacting a localized area of tissue with a gradient of one or more angiogenic factors or a nucleic acid encoding one or more angiogenic factors, such that directed vascular growth along the gradient is achieved.
- Such directed vascular growth can be used to achieve interconnection and/or intraconnection of blood vessels (e.g., to circumvent blood flow around a blockage within a blood vessel).
- the angiogenic factor or nucleic acid is released in a gradient using a biocompatible material which is contacted with (e.g., implanted within) the localized area of tissue.
- the angiogenic factor is associated with the biocompatible material (e.g., absorbed onto the biocompatible material) such that it is released onto surrounding tissue. This can be achieved by treating the biocompatible material with the angiogenic factor prior to contact with (e.g., implantation into) a selected area of tissue.
- the angiogenic factor is then released from the biocompatible material onto the surrounding tissue in a directed gradient determined by the placement of the biocompatible polymer
- Suitable biocompatible materials include, for example, polymers or threads which incorporate the angiogenic factor.
- the biocompatible material is an absorbable thread, such as polyglyconate monofilament, poliglecaprone 25-(Monocryl), polydiaxonone (PDS II), polyglactin 910, polyglycolic acid, Biodyn glycomer 631, chromic surgical gut or plain surgical gut.
- Figure 1 is a graph comparing levels of angiogenesis in the Matrigel model using a low dose of transduced cells encoding GFP alone (control), NEGF-A, NEGF-C, NEGF-D bFGF or PDGF-BB.
- C57B1/10 mice were each injected subcutaneously into the abdominal with a low dose of 3 x 10 5 retrovirally transduced autologous myoblast cells, suspended in 0.4ml of Matrigel. Mice were sacrificed 13 days later and the matrigel pellet and a section of the abdominal muscle adjacent to the pellet was removed. Samples were sectioned and the number of microvessels in the abdominal muscle was quantified by visual inspection of sections under the microscope.
- FIG. 2 is a graph comparing levels of angiogenesis in the Matrigel model using a high dose of cells transduced to express bFGF, NEGF-A and PDGF-BB. C57B1/10 mice were each injected with a high cell dose of 2 x 10 6 retrovirally transduced autologous myoblast cells suspended in 0.4ml of Matrigel.
- PDGF-BB was as potent as either bFGF or NEGF-A at stimulating angiogenesis.
- Figure 3 shows photographs of mouse corneas 6 days following the implantation of pellets coated with control saline (A), PDGF-BB (B), NEGF-A (C) or bFGF (D) alone.
- Bottom panels Quantification of the angiogenic effect elicited by each factor. Vessel length (E), clock hours (F) and area (G) are shown.
- Figure 4 shows photographs of mouse corneas 6 days following the implantation of pellets coated with VEGF-A alone (left panel), bFGF (middle panel) or both factors combined (right panel).
- (B) shows the quantification of the angiogenic effect elicited by each growth factor in terms of clock hours (left panel), vessel length (middle panel) and area (right panel).
- Figure 5 shows photographs of mouse corneas 6 days post- transplantation of pellets coated with bFGF alone (left panel) or bFGF combined with PDGF-BB (middle and right panels). Bottom panels show photographs of mouse corneas 6 days post-transplantation of pellets coated with either VEGF-A alone (left panel) or VEGF-A combined with PDGF-BB (right panel).
- Figure 6 is a graph comparing the quantification of angiogenesis in the mouse cornea model using PDGF-BB, VEGF-A or bFGF either alone or in combination.
- Corneal micropockets were created with a cataract knife in the eyes of 8-week old C57B1/6 mice.
- aluminum sulfate pellets coated with between 80 and 160ng of recombinant human PDGF-BB, VEGF-A, bFGF or combinations thereof were implanted and mice were monitored daily. A total of 5 mice were transplanted per group. The area of newly grown vessels was assessed 5 days post implantation. Mice implanted with control pellets showed no evidence of angiogenesis.
- bFGF stimulated the highest level of angiogenesis followed by VEGF-A and PDGF-BB.
- the level of angiogenesis stimulated by VEGF-A in combination with PDGF-BB was equivalent to that observed for bFGF alone.
- the most potent combination was PDGF-BB and bFGF.
- PDGF-BB and bFGF together stimulated the greatest level of angiogenesis, significantly greater than that observed for VEGF-A and bFGF.
- FIG. 7 is a schematic illustration of the experimental strategy to make heparin sepharose/alginate microcapsules.
- Heparin sepharose beads (Pharmacia: 50- 150 Dm in size) are mixed with a solution of sodium alginate to a final concentration of 200mg/ml.
- the heparin sepharose/alginate solution is then loaded into a 5ml syringe and slowly injected into a coaxial airflow system constructed at Genetix.
- the coaxial air flow creates a mist of the heparin sepharose/alginate solution which drops into a 1.5% calcium chloride bath.
- the alginate hits the calcium solution the alginate becomes cross-linked, forming a solid gel capsule roughly in the shape of a sphere.
- the size of the microcapsules can vary greatly from 50 - 400 Dm. Large microcapsules (greater than 200 Dm in size) are removed from the capsule mixture using a 200 Dm sieve. Once formed the capsules are washed twice in sterile water and stored in buffer composed of 0.9% sodium chloride and ImM calcium chloride. Capsules are loaded with recombinant human PDGF-BB by incubation in binding buffer (0.9% NaCl, ImM CaC12 and 0.05% gelatin) at 4°C overnight (-16 hours) with gentle shaking. The next day the capsules are removed, washed twice in binding buffer and either cultured in vitro to determine the kinetics of PDGF-BB release or injected in vivo to assess angiogenesis. The efficiency of PDGF-BB uptake is quantified by ELISA of the binding buffer following removal of the capsules.
- Figure 8 is a graph showing that heparin sepharose/alginate capsules bind large amounts of recombinant human PDGF-BB. Shown is the amount of PDGF-BB absorbed by 3000 capsules following incubation with various quantities of growth factor. The amount of PDGF-BB remaining in the binding buffer following incubation with capsules was quantified by ELISA. Three thousand capsules were able to absorb at least 35 ⁇ g of PDGF-BB representing 13 ng of PDGF-BB per capsule.
- Figure 9 is a graph showing that heparin sepharose/alginate microcapsules provide slow, high level and long term release of bound PDGF-BB in vitro.
- Ten ⁇ g of recombinant human PDGF-BB was incubated with three different types of test samples. The first test sample was composed of non-encapsulated heparin sepharose beads while the second and third groups were composed of alginate encapsulated heparin sepharose beads made using either a 1.2% or a 1.6% alginate solution.
- Three thousand beads/microcapsules were incubated with PDGF-BB at 4°C overnight with gentle shaking.
- ELISA analysis of the binding buffer the next day showed absorption of 90% (9 ⁇ g) of the PDGF by the capsules.
- the beads/microcapsules were washed, resuspended in 5mls of serum free medium and incubated at 37°C. Every 24 hours the medium was changed and the amount of PDGF- BB present in the medium quantified by ELISA. A slow, sustained release of approximately 0.5-3% of the total bound PDGF-BB (representing 125-250ng) was detected each day for a minimum of 14 days, the longest time point tested. Importantly, the proportion of PDGF-BB released per day is equivalent to the amount of PDGF-BB that was estimated to be secreted by muscle cells transduced with the PDGF-BB retro virus in the foregoing Matrigel experiments. The release kinetics for non- encapsulated heparin sepharose beads was better than those observed for the alginate encapsulated heparin sepharose.
- Figure 10 is a graph showing that PDGF-BB microcapsules potently stimulate angiogensis in vivo in the stringent Matrigel model.
- Three thousand microcapsules loaded with l ⁇ g or lO ⁇ g of PDGF-BB were mixed with 400 ⁇ l of Matrigel and subcutaneously injected into the abdominal region of C57B1/10 mice. Thirteen days later mice were sacrificed, the pellets and a section of the adjacent abdominal muscle was removed, fixed, sectioned and the number of microvessels quantified by visual inspection of the sections under the microscope. The results showed that the number of microvessels in mice receiving microcapsules loaded with lOmg of PDGF-BB was 2.5- fold greater than that of control mice.
- FIG 11 is a graph showing that PDGF-BB microcapsules stimulate angiogenesis in infarcted rat hearts 3 weeks post-injection.
- Infarcted rat hearts were injected with 1600 microcapsules containing ⁇ g (control) or 18 ⁇ g of PDGF-BB in a volume of 20 ⁇ l.
- Three weeks post injection rats were sacrificed, hearts were removed, fixed, sectioned and the number of microvessels within the infarct region quantified by visual inspection under a microscope. Shown is the number of microvessels per 5 high power fields for recipients of control and PDGF-BB microcapsules.
- Rats injected with PDGF-BB microvessels showed an approximate 2-fold increase in the number of microvessels as compared to control rats.
- Figure 12 shows an analysis of cardiac function in rats injected with control vs. PDGF-BB microcapsules following myocardial infarction.
- Left ventricular pressure (LVP), dP/dT, neg dP/dT and tau were measured prior to sacrifice at 3 weeks post injection.
- Left ventricular pressure (LNP) is the maximum pressure in the left ventricle during contraction.
- the dP/dT variable is the first derivative of the pressure wave and is separately viewed for the upstroke (dP/dT) and the downstroke (neg dP/dT).
- the upstroke (dP/dT) is a measure of contractility and reflects the condition of the muscle independent of the pressure.
- Neg dP/dT reflects the relaxation of the muscle, which together with the relaxation constant, tau, provides information on the stiffness of the ventricular wall following infarction.
- a significant improvement in all parameters was detected in rats injected with PDGF-BB microcapsules. Rats injected with PDGF-BB microcapsules showed a 25% increase in left ventricular pressure, a 2-3 fold increase in cardiac contractility/relaxation and a 2.5-3 fold decrease in the relaxation constant tau.
- Figure 13 is a graph showing that PDGF-BB and bFGF delivered by slow release microcapsules potently synergize to stimulate angiogensis in vivo in the stringent Matrigel model.
- Three thousand microcapsules loaded with l ⁇ g of bFGF were mixed with 400 ⁇ l of Matrigel and subcutaneously injected into the abdominal region of C57B1/10 mice. Thirteen days later mice were sacrificed, the pellets and a section of the adjacent abdominal muscle was removed, fixed, sectioned and the number of microvessels quantified by visual inspection of the sections under the microscope. The results showed that the number of microvessels in mice receiving bFGF + PDGF-BB microcapsules was 4-fold greater than that of mice implanted with either growth factor alone.
- Figure 14 is a schematic illustration of the structure of various angiogenic expression plasmids. All vectors were constructed using the pCI vector backbone from Promega. All vectors contained the Cytomegalovirus immediate-early enhancer/promoter region, a chimeric intron and the late poly adenylation signal from SV40. The cDNA encoding either human PDGF-BB, NEGF-A or bFGF was inserted into this vector downstream of the chimeric intron.
- a cD ⁇ A encoding for the mature PDGF-BB protein was cis-linked to the secretory signal from the murine IgGkappa immunoglobulin light chain gene while the NEGF-A cD ⁇ A utilized its endogenous secretory signal. Since endogenous bFGF is not secreted by the usual Golgi pathway and prior groups have had difficulty in obtaining high level secretion of bFGF from cells transduced with the bFGF cD ⁇ A, the bFGF cD ⁇ A was linked in cis to the secretory signal from the human Interleukin-2 cD ⁇ A.
- test animals are anesthetized and intubated. The chest wall is opened and a myocardial infarct is created by tying off the anterior descending artery. 180 ⁇ g of control or test expression plasmid is injected into the heart wall in a volume of 20 ⁇ l. Cardiac function is assessed 3 weeks post injection. Animals are sacrificed, the heart is removed and efficiency of plasmid uptake is assessed by staining with X-gal. The size of the infarct and the extent of angiogenesis is quantified.
- the present invention provides, for the first time, methods for promoting angiogenesis and treating such ischemia using particular angiogenic factors, such as PDGF-BB, as well as particular combinations of factors (e.g., combinations which include PDGF-BB).
- angiogenic factors such as PDGF-BB
- combinations of factors e.g., combinations which include PDGF-BB
- the present invention also provides improved methods for delivering the factors to increase their efficacy, for example, by enabling directed and/or controlled release of the angiogenic factors onto surrounding tissue (e.g., ischemic myocardium).
- angiogenic factor refers to any known protein factor capable of promoting growth of new blood vessels from existing vasculature ("angiogenesis"). Suitable angiogenic factors for use in the invention include, for example, PDGF-BB, PDGF-AA, M-CSF, GM-CSF, NEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, neuropilin, FGF-1 , FGF-2(bFGF), FGF-3, FGF-4, FGF-5, FGF-6, Angiopoietin 1, Angiopoietin 2, erythropoietin, BMP-2, BMP-4, BMP-7, TGF-beta, IGF-1, Osteopontin, Pleiotropin, Activin, Endothelin-1 and combinations thereof.
- angiogenic factor also refers to functional analogues of the above- mentioned factors.
- Such functional analogues include, for example, functional peptides or portions of the factors.
- Functional analogues also include anti-idiotypic antibodies which bind to the receptors of the factors and, thus, mimic the activity of the factors in promoting angiogenesis. Methods for generating such anti-idiotypic antibodies are well known in the art and are described, for example, in WO 97/23510, the contents of which are incorporated by reference herein.
- Antigens have specific epitopes to which certain antibodies will bind.
- the region of the antibody that specifically interacts with the epitopes on the antigen is called the antigen combining site.
- the antigen combining site is composed of a collection of idiotopes which are unique sequences on the antibody that specifically interact with the epitopes on the antigen.
- the specific collection of idiotopes that interact with the epitopes on the antigen is defined as an antibody's "idiotype".
- an anti- idiotype antibody is an antibody that is directed against the antigen combining site of the first antibody. Anti-idiotype antibodies combine with those specific sequences and may resemble or act as the epitope to which the first antibody reacts.
- This anti-idiotype antibody may then mimic the biological activity of bFGF itself by binding to the bFGF receptor and activating it.
- anti-idiotype antibodies as growth factor analogues
- antibodies have much greater half lives and therefore their potency is maintained for a greater length of time in vivo.
- the levels of growth factors that are required to achieve a biological effect can, in certain instances, produce adverse reactions such as toxicity and hypotension. Since lower levels of anti-idiotype antibodies may be required to produce the same biological effect these adverse side effects may be prevented.
- Angiogenic factors used in the present invention can be purified from their native sources or produced by recombinant expression and subsequently administered to patients as a protein composition. Alternatively, the factors can be administered in the form of an expression plasmid encoding the factors, as is described in further detail below.
- suitable expression plasmids is well known in the art. Particular angiogenic expression plasmids for use in the invention are shown in Figure 14 and are described in Example 1.
- Suitable vectors for constructing expression plasmids include, for example, adenoviral vectors, retroviral vectors, adeno-associated viral vectors, RNA vectors, liposomes, cationic lipids, lentiviral vectors and transposons.
- the present invention provides novel methods and compositions for promoting angiogenesis to promote angiogenesis and to treat a variety of tissue ischemias.
- Selected angiogenic factors or synergistic combinations of factors, functional analogues of such factors or combinations of factors, or nucleic acids encoding such factors or combinations of factors, are delivered to a localized area of tissue in an amount effective to induce angiogenesis within the area of tissue.
- the invention provides a method of promoting angiogenesis comprising delivering PDGF-BB to a localized area of tissue in an amount effective to induce angiogenesis within the area of tissue.
- the PDGF-BB can be delivered either alone or in combination with another angiogenesis-promoting factor.
- Particularly preferred combinations include PDGF-BB combined with bFGF and/or VEGF-A. DELIVERY VEHICLES FOR ANGIOGENIC FACTORS
- the present invention provides a means for delivering angiogenic factors to a localized area of tissue in a controlled, sustained fashion.
- One problem in using purified (e.g., recombinant) angiogenic proteins to stimulate angiogenesis for the treatment of myocardial and peripheral tissue ischemia can be the short half-life of the protein upon injection in vivo. This problem is addressed by way of the present invention using slow-release heparin sepharose-containing microcapsules in an amount effective to induce angiogenesis within the area of tissue.
- One property that many angiogenic factors share is the ability to bind to heparin, a highly sulfated glycosaminoglycan that plays a role in anti-coagulation in vivo.
- the microcapsules are injected or surgically implanted into localized areas of tissue.
- the microcapsules are delivered to localized areas of tissue using the NOGA system (Biosense).
- NOGA is a 3 dimensional catheter based transmyocardial injection system. A catheter is inserted into a major vein/artery and is snaked up into either of the ventricals of the heart. The end of the catheter contains a needle and a space in which therapeutic agents can be inserted and subsequently injected intra-myocardially into the damaged areas of the heart muscle. This delivery method is much easier and safer for the patient and is much more efficacious than other methods of delivery including intracoronary injections or placing therapeutic agents against the wall of the heart.
- microcapsules of the present invention can be used with the system.
- the microcapsules are composed of single heparin sepharose beads which optionally can be coated with a thin layer of alginate polymer.
- the microcapsules are made up of uncoated heparin sepharose beads, heparin sepharose beads coated with a single layer of alginate polymer, heparin sepharose beads coated with poly-ethylene glycol (PEG) polymer or heparin sepharose beads coated with alternating layers of alginate and PEG.
- PEG poly-ethylene glycol
- the microcapsules can also be made small enough for use in the NOGA delivery system.
- the microcapsules typically range from 1-200 microns in size.
- they are able to absorb large quantities of angiogenic factors, such as FGF-2, VEGF-A and PDGF-BB, and slowly release the factors over extended periods of time at levels which are able to stimulate the growth of new blood vessels in vivo.
- the present invention provides a means for delivering angiogenic factors to a localized area of tissue using a gradient of one or more angiogenic factors or a nucleic acid encoding one or more angiogenic factors, such that directed vascular growth along the gradient is achieved.
- Angiogenic factors such as those described in the preceding examples, work by providing a gradient of angiogenic factor that stimulates the chemotaxis and proliferation of endothelial cells, and their supporting cells towards the source of the factor. Regulating the growth of new vessels from existing vasculature (angiogenesis) that effectively bypass an arterial lesion requires strict spatial and temporal control. Accordingly, by forming a directed gradient of angiogenic factors in accordance with the present invention, interconnection and/or intraconnection of blood vessels (e.g., to circumvent blood flow around a blockage within a blood vessel) can be achieved.
- the angiogenic factor (or a nucleic acid encoding the factor) is released in a gradient using a biocompatible material which contains the factor such that the factor is released onto surrounding tissue when the biocompatible material is contacted with (e.g., implanted within) the tissue.
- a biocompatible material which contains the factor such that the factor is released onto surrounding tissue when the biocompatible material is contacted with (e.g., implanted within) the tissue.
- This can be achieved by treating the biocompatible material with the angiogenic factor prior to contact with (e.g., implantation into) a selected area of tissue in a manner which allows for release of the factor from the material in vivo.
- the biocompatible material is then contacted with (e.g., implanted into) a localized area of tissue in a configuration which provides a directed gradient of the angiogenic factor once it is released from the material.
- Suitable biocompatible materials for use in the invention include, for example, polymers or threads which incorporate the angiogenic factor.
- the biocompatible material is an absorbable thread, such as polyglyconate monofilament, poliglecaprone 25-(Monocryl), polydiaxonone (PDS II), polyglactin 910, polyglycolic acid, Biodyn glycomer 631, chromic surgical gut or plain surgical gut.
- the biocompatible material can be coated with one or several angiogenic factors to allow delivery of growth factor or growth factor combinations that provide the optimal angiogenic stimulus.
- the biocompatible material can also be engineered to release certain growth factors at specific rates and at specific times that may help mimic the natural angiogenic process more closely.
- EXAMPLE 1 Construction of Retroviral Vectors Containing Angiogenic cDNAs , Analysis of Virus Titer and Assessment of Stable Gene Transfer
- PDGF-BB In order to provide stable, high-level delivery of PDGF-BB in the Matrigel model, primary myoblasts from C57B1/10 mice were transduced with retroviral vectors encoding human PDGF-BB. To compare the angiogenic potential of PDGF-BB to other known angiogenic agents, retroviral vectors encoding human VEGF-A165, VEGF-C, VEGF-A, VEGF-D, PDGF-BB, or bFGF also were constructed and tested. All vectors are shown schematically in Figure 14.
- VEGF-C, VEGF-D and PDGF-BB cDNAs encode proteins which are inactive (or less active in the case of PDGF-BB) in their non- processed form
- vectors containing cDNAs encoding the mature forms of the aforementioned proteins linked to the powerful secretory signal from the murine IgG kappa immunoglobulin gene were constructed.
- All vectors also contained the gene encoding the green fluorescent protein (GFP) to enable the fast efficient and non-toxic selection of transduced target cells by fluorescence activated cell sorting (FACS).
- FACS sorting is used to isolate the brightest 10% of GFP positive retrovirally transduced cells. Since both GFP and the angiogenic cDNA are translated from the same mRNA molecule, this ensures that the sorted cells also express high levels of the angiogenic protein. A strong correlation between the fraction of top GFP expressing cells and the amount of angiogenic protein secreted by the sorted cells exists. This result, in combination with data from Southern blot analysis of transduced cells which showed 3-6 proviral copies per genome in sorted GFP positive cells, indicates that the levels of angiogenic protein production and secretion are at their maximal level using this system.
- Vectors were tested for stability of gene transfer and virus titer.
- Vectors demonstrated a virus titer ranging from approximately 5 x 10 5 - 1.2 x 10 6 infectious virus particles per ml and all vectors showed stable transfer of the angiogenic cDNA to target primary skeletal muscle myoblasts from C57B1/10 mice.
- all myoblast samples were also marked by infection with a retroviral vector encoding a ⁇ - galactosidase/neomycin ( ⁇ -GEO) resistance fusion gene.
- ⁇ -GEO ⁇ - galactosidase/neomycin
- the potency of the angiogenic proteins secreted from the transduced myoblasts described in Example 1 was assessed in vivo using the stringent Matrigel assay.
- 3 x 10 5 - 2 x 10 6 transduced myoblasts were suspended in Matrigel and injected subcutaneously into the dorsal abdominal region of C57B1/10 mice.
- the Matrigel pellets in addition to a section of abdominal muscle adjacent to the Matrigel pellet, were recovered 13 days post-injection. Following harvesting of the Matrigel pellet and the adjacent abdominal muscle 13 days post-injection, Matrigel pellets were stained with X- gal and analyzed for the presence of blue, retrovirally transduced myoblasts. In addition, the number of microvessels in the adjacent abdominal muscle was quantified by visual inspection.
- mice Corneal micropockets were created with a cataract knife in the eye of 8-week old C57B1/6 mice. Into this pocket, a 0.34mm X 0.34mm sucrose aluminum sulfate pellet coated with hydron polymer containing 160ng of recombinant human PDGF-BB, 160ng of human VEGF-A, or 80 ng of human bFGF was implanted and mice were monitored daily. While those mice implanted with control pellets showed no evidence of angiogenesis, all mice receiving PDGF-BB coated pellets showed evidence of potent angiogenesis (see Figure 3).
- recombinant PDGF-BB protein can potently stimulate the growth of new vessels in both the mouse Matrigel and corneal assays.
- PDGF-BB by itself, although inducing a clear and potent angiogenic response, was less potent than either VEGF-A or bFGF ( Figure 3).
- Figure 3 The differences observed for the Matrigel and mouse corneas models could be explained by the production of additional endogenous angiogenic factors by transduced myoblasts that synergize more readily with PDGF-BB compared to VEGF-A.
- the levels of recombinant VEGF-A and PDGF- BB produced in vivo may differ to the levels produced in vitro.
- This polymer is able to form gels through chemical cross-linking with multivalent cations such as calcium.
- the capsules were forced through a 250 ⁇ m sieve, washed twice in sterile water and stored in buffer composed of 0.9% sodium chloride and ImM calcium chloride. Visual analysis of the capsules under the microscope showed that the vast majority of microcapsules were composed of individual heparin sepharose beads coated with a thin layer of alginate. Heparin-sepharose/alginate microcapsules were incubated overnight at 4 degrees
- mice The ability of the heparin-sepharose/alginate microcapsules to stimulate angiogenesis in vivo was assessed using the stringent Matrigel assay.
- Three thousand microcapsules loaded with 1 ⁇ g or 1 O ⁇ g of PDGF-BB were mixed with 400 ⁇ l of Matrigel and subcutaneously injected into the abdominal region of C57B1/10 mice. Thirteen days later mice were sacrificed, the pellets and a section of the adjacent abdominal muscle was removed, fixed, sectioned and the number of microvessels quantified by visual inspection of the sections under the microscope. As shown in Figure 10, the number of microvessels in mice receiving microcapsules loaded with lOmg of PDGF-BB was 2.5-fold greater than that of control mice.
- PDGF-BB and bFGF delivered by slow release microcapsules synergize to stimulate angiogensis in vivo in the stringent Matrigel model.
- Three thousand microcapsules loaded with l ⁇ g of bFGF were mixed with 400 ⁇ l of Matrigel and subcutaneously injected into the abdominal region of
- mice C57B1/10 mice. Thirteen days later mice were sacrificed, the pellets and a section of the adjacent abdominal muscle was removed, fixed, sectioned and the number of microvessels quantified by visual inspection of the sections under the microscope.
- Figure 13 shows that the number of microvessels in mice receiving bFGF + PDGF-BB microcapsules was 4-fold greater than that of mice implanted with either growth factor alone.
- PDGF-BB microcapsules were also tested for their ability to stimulate angiogenesis in infarcted rat hearts 3 weeks post-injection.
- Infarcted rat hearts were injected with 1600 microcapsules containing ⁇ g (control) or 18 ⁇ g of PDGF-BB in a volume of 20 ⁇ l.
- Three weeks post injection rats were sacrificed, hearts were removed, fixed, sectioned and the number of microvessels within the infarct region quantified by visual inspection under a microscope (i.e., number of microvessels per 5 high power fields for recipients of control and PDGF-BB microcapsules).
- rats injected with PDGF-BB microvessels showed an approximate 2-fold increase in the number of microvessels as compared to control rats.
- heparin-sepharose/alginate microcapsules were also assessed using the ischemic rat heart model as follows.
- Adult male rats were anesthetized, intubated and ventilated with a Harvard respirator. Under sterile conditions, a left lateral thoractomy was performed. The heart was exposed and the left descending coronary artery was ligated with a 8-0 Prolene suture.
- each heart was injected twice intramyocaridally with lO ⁇ l of a buffer suspension containing approximately 800 heparin sepharose/alginate microcapsules with 9 ⁇ g of absorbed recombinant human PDGF-BB protein.
- a total of 1600 microcapsules containing 18 ⁇ g of human PDGF-BB protein were injected into each rat heart.
- the lungs were then inflated and the wound was closed in layers.
- cardiac function was assessed using a variety of parameters including left ventricular pressure (LVP), dP/dT (a measure of cardiac contractility), negative dP/dT (a measure of relaxation of the cardiac muscle) and tau (the relaxation constant) (see Figure 12).
- LVP left ventricular pressure
- dP/dT a measure of cardiac contractility
- negative dP/dT a measure of relaxation of the cardiac muscle
- tau the relaxation constant
- angiogenesis regulates the growth of new vessels from existing vasculature that effectively bypass an arterial lesion requires strict spatial and temporal control.
- Angiogenic factors such as those described in the preceding examples, work by providing a gradient of angiogenic factor that stimulates the chemotaxis and proliferation of endothelial cells, and their supporting cells towards the source of the factor.
- biocompatible absorbable threads containing angiogenic factors can be employed to provide a small, highly localized and orderly gradient of angiogenic factors in the appropriate and crucial areas. This enables the creation of a
- molecular road map that directs the growth of new vessels from around the site of the arterial occlusion to join again at a point below or downstream of the blockage.
- absorbable surgical threads can be coated with the appropriate angiogenic factors (e.g., PDGF-BB, FGF-2, VEGF-A and PDGF-B). Such threads can then be surgically placed at the site of arterial occlusion such that they provide a clear spatial direction and gradient of angiogenic factor(s) to direct the generation of new vessels around the block.
- the biocompatible threads can be coated with one or several angiogenic factors to allow delivery of growth factor or growth factor combinations that provide the optimal angiogenic stimulus. Moreover, such threads can be engineered to release certain growth factors at specific rates and at specific times that may help mimic the natural angiogenic process more closely.
- Figure 14 shows a variety of expression plasmids encoding angiogenic factors that can be administered directly to localized areas of tissue to promote angiogenesis.
- the plasmids encode biologically active PDGF-BB protein
- supernatant from 293T cells transiently transfected with the PDGF-BB expression plasmid was added to NIH 3T3 cells growing under serum free conditions. Seventy two hours later cells were trypsinized, spun down and counted using a hemocytometer. The results showed that the PDGF-BB supernatant specifically and potently induced the proliferation of NIH3T3 cells.
- test animals e.g., rats
- control vs. angiogenic plasmids e.g., PDGF-BB expression plasmids
- test animals can be anesthetized and intubated.
- the chest wall is opened and a myocardial infarct is created by tying off the anterior descending artery.
- 180 ⁇ g of control or test expression plasmid is injected into the heart wall in a volume of 20 ⁇ l.
- Cardiac function is assessed 3 weeks post injection. Animals are sacrificed, the heart is removed and efficiency of plasmid uptake is assessed by staining with X-gal. The size of the infarct and the extent of angiogenesis is quantified.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02714757A EP1355659A2 (fr) | 2001-01-26 | 2002-01-18 | Methodes et compositions permettant de stimuler l'angiogenese |
AU2002247007A AU2002247007B2 (en) | 2001-01-26 | 2002-01-18 | Use of compositions containing PDGF-BB for promoting angiogenesis |
CA002436076A CA2436076A1 (fr) | 2001-01-26 | 2002-01-18 | Methodes et compositions permettant de stimuler l'angiogenese |
JP2002559052A JP4434584B2 (ja) | 2001-01-26 | 2002-01-18 | 血管新生を促進する方法及び組成物 |
US10/198,917 US20030139333A1 (en) | 2002-01-18 | 2002-07-19 | Methods and compositions for promoting angiogenesis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26445701P | 2001-01-26 | 2001-01-26 | |
US60/264,457 | 2001-01-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002058718A2 true WO2002058718A2 (fr) | 2002-08-01 |
WO2002058718A3 WO2002058718A3 (fr) | 2003-04-17 |
Family
ID=23006154
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/001666 WO2002058718A2 (fr) | 2001-01-26 | 2002-01-18 | Methodes et compositions permettant de stimuler l'angiogenese |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1355659A2 (fr) |
JP (1) | JP4434584B2 (fr) |
AU (1) | AU2002247007B2 (fr) |
CA (1) | CA2436076A1 (fr) |
WO (1) | WO2002058718A2 (fr) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004533411A (ja) * | 2001-01-26 | 2004-11-04 | カイロン コーポレイション | 血管形成的に有効なfgf−2の単位用量および使用方法 |
JP2005168654A (ja) * | 2003-12-09 | 2005-06-30 | Kissei Pharmaceut Co Ltd | 増殖因子結合低分子ヘパリン修飾体 |
WO2007034320A3 (fr) * | 2005-09-26 | 2007-10-04 | Proteins & Peptides Man | Complexe polymere amphiphile-pdgf |
FR2914191A1 (fr) * | 2007-03-29 | 2008-10-03 | Proteins & Peptides Man | Composition angiogenique. |
WO2010035122A2 (fr) * | 2008-09-26 | 2010-04-01 | Adocia | Complexe constitue d'un polysaccharide et d'une hpb |
WO2010078624A1 (fr) * | 2009-01-07 | 2010-07-15 | Vegenics Limited | Matériaux et méthodes pour le traitement de l’hypertension |
WO2016147005A1 (fr) * | 2015-03-19 | 2016-09-22 | Cell Therapy Limited | Composition comprenant le facteur de croissance des fibroblastes basique (fgf-2) et le facteur de croissance dérivé des plaquettes (pdgf) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1948210A4 (fr) * | 2005-11-08 | 2010-07-14 | Found Biomedical Res & Innov | Methode de traitement d'une maladie cardiaque ischemique |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990000060A1 (fr) * | 1988-06-30 | 1990-01-11 | Collagen Corporation | Matrices collagenes de cicatrisation de blessures et leur procede de production |
WO1991016009A1 (fr) * | 1990-04-17 | 1991-10-31 | Curative Technologies, Inc. | Procede utilise pour recouvrir des surfaces de protheses avec des cellules de mammiferes |
US5128321A (en) * | 1986-08-13 | 1992-07-07 | Zymogenetics, Inc. | PDGF analogs and methods of use |
WO1994025056A2 (fr) * | 1993-04-29 | 1994-11-10 | Washington University | Utilisation du facteur de croissance derive des plaquettes pour l'amelioration de la circulation collaterale |
WO1997012601A2 (fr) * | 1995-10-06 | 1997-04-10 | Ethicon, Inc. | Formulations de gel contenant des facteurs de croissance |
WO2000041732A1 (fr) * | 1999-01-19 | 2000-07-20 | The Children's Hospital Of Philadelphia | Compositions hydrogel pour l'administration controlee de vecteurs viraux, et leurs procedes d'utilisation |
-
2002
- 2002-01-18 EP EP02714757A patent/EP1355659A2/fr not_active Ceased
- 2002-01-18 WO PCT/US2002/001666 patent/WO2002058718A2/fr active Application Filing
- 2002-01-18 AU AU2002247007A patent/AU2002247007B2/en not_active Ceased
- 2002-01-18 JP JP2002559052A patent/JP4434584B2/ja not_active Expired - Fee Related
- 2002-01-18 CA CA002436076A patent/CA2436076A1/fr not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5128321A (en) * | 1986-08-13 | 1992-07-07 | Zymogenetics, Inc. | PDGF analogs and methods of use |
WO1990000060A1 (fr) * | 1988-06-30 | 1990-01-11 | Collagen Corporation | Matrices collagenes de cicatrisation de blessures et leur procede de production |
WO1991016009A1 (fr) * | 1990-04-17 | 1991-10-31 | Curative Technologies, Inc. | Procede utilise pour recouvrir des surfaces de protheses avec des cellules de mammiferes |
WO1994025056A2 (fr) * | 1993-04-29 | 1994-11-10 | Washington University | Utilisation du facteur de croissance derive des plaquettes pour l'amelioration de la circulation collaterale |
WO1997012601A2 (fr) * | 1995-10-06 | 1997-04-10 | Ethicon, Inc. | Formulations de gel contenant des facteurs de croissance |
WO2000041732A1 (fr) * | 1999-01-19 | 2000-07-20 | The Children's Hospital Of Philadelphia | Compositions hydrogel pour l'administration controlee de vecteurs viraux, et leurs procedes d'utilisation |
Non-Patent Citations (8)
Title |
---|
EDELMAN E.R. ET AL.: "Controlled and modulated release of basic fibroblast growth factor." BIOMATERIALS, vol. 12, no. 7, September 1991 (1991-09), pages 619-626, XP000226106 * |
FRANK K R ET AL: "CONTROLLED RELEASE OF BIOACTIVE GROWTH FACTORS FROM A BIODEGRADABLE DELIVERY SYSTEM" PHARMACEUTICAL RESEARCH, NEW YORK, NY, US, vol. 11, no. 10, October 1994 (1994-10), page S88,ANBIOTEC2070 XP001068790 ISSN: 0724-8741 * |
KAWAI K ET AL: "Accelerated tissue regeneration through incorporation of basic fibroblast growth factor-impregnated gelatin microspheres into artificial dermis - targeted delivery systems" BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 21, no. 5, March 2000 (2000-03), pages 489-499, XP004185546 ISSN: 0142-9612 * |
LIECHTY K.W. ET AL.: "Adenoviral-mediated overexpression of platelet-derived growth factor-B corrects ischemic impaired wound healing." J. INVEST. DERMATOL., vol. 113, no. 3, September 1999 (1999-09), pages 375-383, XP002211469 * |
PARK Y J ET AL: "Controlled release of platelet-derived growth factor-BB from chondroitin sulfate-chitosan sponge for guided bone regeneration" JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 67, no. 2-3, July 2000 (2000-07), pages 385-394, XP004199184 ISSN: 0168-3659 * |
PARK Y.J.: "Controlled release of PDGF from porous poly(L-lactide) membranes for guided tissue regeneration." J. CONTROLLED RELEASE., vol. 51, 1998, pages 201-211, XP004113628 * |
STEED D L ET AL: "CLINICAL EVALUATION OF RECOMBINANT HUMAN PLATELET-DERIVED GROWTH FACTOR FOR THE TREATMENT OF LOWER EXTREMITY DIABETIC ULCERS" JOURNAL OF VASCULAR SURGERY, C.V. MOSBY CO., ST. LOUIS, MO, US, vol. 1, no. 21, January 1995 (1995-01), pages 71-81, XP001088899 ISSN: 0741-5214 * |
YLÄ-HERTTUALA S. AND MARTIN J.F.: "Cardiovascular gene therapy" LANCET, vol. 355, 15 January 2000 (2000-01-15), pages 213-222, XP002211470 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004533411A (ja) * | 2001-01-26 | 2004-11-04 | カイロン コーポレイション | 血管形成的に有効なfgf−2の単位用量および使用方法 |
JP2005168654A (ja) * | 2003-12-09 | 2005-06-30 | Kissei Pharmaceut Co Ltd | 増殖因子結合低分子ヘパリン修飾体 |
AU2006293613B2 (en) * | 2005-09-26 | 2012-05-17 | Adocia | PDGF amphiphilic polymer complex |
WO2007034320A3 (fr) * | 2005-09-26 | 2007-10-04 | Proteins & Peptides Man | Complexe polymere amphiphile-pdgf |
US8241620B2 (en) | 2005-09-26 | 2012-08-14 | Adocia | Complex polymere amphiphile-PDGF |
FR2914191A1 (fr) * | 2007-03-29 | 2008-10-03 | Proteins & Peptides Man | Composition angiogenique. |
WO2008120085A3 (fr) * | 2007-03-29 | 2009-09-11 | Adocia | Composition angiogenique comprenant un complexe entre un polymere amphiphile et un pdgf |
WO2008120085A2 (fr) * | 2007-03-29 | 2008-10-09 | Adocia | Composition angiogenique comprenant un complexe entre un polymere amphiphile et un pdgf |
WO2010035122A2 (fr) * | 2008-09-26 | 2010-04-01 | Adocia | Complexe constitue d'un polysaccharide et d'une hpb |
WO2010035122A3 (fr) * | 2008-09-26 | 2011-05-05 | Adocia | Complexe constitue d'un polysaccharide et d'une hpb |
US8367640B2 (en) | 2008-09-26 | 2013-02-05 | Adocia | Complex consisted of a polysaccharide and an HBP |
WO2010078624A1 (fr) * | 2009-01-07 | 2010-07-15 | Vegenics Limited | Matériaux et méthodes pour le traitement de l’hypertension |
WO2016147005A1 (fr) * | 2015-03-19 | 2016-09-22 | Cell Therapy Limited | Composition comprenant le facteur de croissance des fibroblastes basique (fgf-2) et le facteur de croissance dérivé des plaquettes (pdgf) |
Also Published As
Publication number | Publication date |
---|---|
AU2002247007B2 (en) | 2006-12-07 |
EP1355659A2 (fr) | 2003-10-29 |
JP4434584B2 (ja) | 2010-03-17 |
WO2002058718A3 (fr) | 2003-04-17 |
JP2005506279A (ja) | 2005-03-03 |
CA2436076A1 (fr) | 2002-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001268149B2 (en) | Methods and compounds for controlled release of recombinant parvovirus vectors | |
Winn et al. | Gene therapy approaches for modulating bone regeneration | |
ES2206342T3 (es) | Dispositivo medico que comprende una superficie sintetica que tiene acido nucleico para la induccion in vivo de su endotelializacion. | |
US20030139333A1 (en) | Methods and compositions for promoting angiogenesis | |
US20080031923A1 (en) | Biologic Replacement for Fibrin Clot | |
US20020172663A1 (en) | Localized myocardial injection method for treating ischemic myocardium | |
JP2006524691A (ja) | 心臓導電系の標的化された領域の遺伝子修飾 | |
CN1198675A (zh) | 含有hgf基因的药物 | |
AU2002247007B2 (en) | Use of compositions containing PDGF-BB for promoting angiogenesis | |
US20080102059A1 (en) | Treatment for arthritis | |
AU772857B2 (en) | Method of inducing angiogenesis | |
AU2002247007A1 (en) | Use of compositions containing PDGF-BB for promoting angiogenesis | |
CN103638002A (zh) | 包囊的肝细胞组合物 | |
WO1989007944A1 (fr) | Procede et dispositif de neovascularisation a localisation controlee | |
EA019099B1 (ru) | Способ направленной доставки трансгена в миокард пациента с ишемией миокарда | |
CN1630538A (zh) | 用vegf-b刺激血管生成 | |
ES2434257T3 (es) | Coágulos de células hematopoyéticas no poliméricos para suministro de agentes activos | |
JP2014218509A (ja) | 遺伝子治療用アデノ随伴ウイルスベクターの長期順行性の心外膜冠動脈注入 | |
WO2001087312A1 (fr) | Utilisation de polymeres polyethyleneglycols (peg) dans la stimulation de l'angiogenese | |
Vranckx et al. | 15 Gene Transfer of Growth Factors for Wound Repair | |
Wang et al. | In vitro circadian ANP secretion by gene transferring cells encapsulated in polycaprolactone tubes: gene chronotherapy | |
WO2007059303A2 (fr) | Compositions pour l'expression coordonnee de vegf et de pdgf, et methodes d'utilisation | |
Davidson | 13 Gene Therapy of Wounds | |
WO2005086684A2 (fr) | Procede de modulation, de regulation et/ou de stabilisation de l'angiogenese | |
EP1556494A2 (fr) | Boite d'expression, vecteur de plasmide a deux cistrons, produit pharmaceutique et leur utilisation en therapie genique angiogenique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 10198917 Country of ref document: US |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002714757 Country of ref document: EP Ref document number: 2436076 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002559052 Country of ref document: JP Ref document number: 2002247007 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2002714757 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |